학술논문
Cost-effectiveness of pembrolizumab for the first-line treatment of patients with unresectable or metastatic MSI-H/dMMR colorectal cancer in the United States
Document Type
Article
Author
Source
In: Journal of Medical Economics . (Journal of Medical Economics, 2022, 25(1):469-480)
Subject
Language
English
ISSN
1941837X
13696998
13696998